Macquarie Group
EGRX

Macquarie Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Macquarie Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-518
Closed -$2.9K – 1965
2024
Q2 		$2.9K Buy
+518
New +$2.26K ﹤0.01% 1771
2022
Q3 		– Sell
-453
Closed -$16.6K – 2334
2022
Q2 		$20K Hold
453
– – ﹤0.01% 2316
2022
Q1 		$22 Hold
453
– – ﹤0.01% 2374
2021
Q4 		$23K Hold
453
– – ﹤0.01% 2366
2021
Q3 		$25K Hold
453
– – ﹤0.01% 2408
2021
Q2 		$19K Hold
453
– – ﹤0.01% 2375
2021
Q1 		$19K Sell
453
-215
-32% -$9.98K ﹤0.01% 2306
2020
Q4 		$31K Hold
668
– – ﹤0.01% 2145
2020
Q3 		$28K Hold
668
– – ﹤0.01% 2089
2020
Q2 		$32K Sell
668
-2,032
-75% -$101K ﹤0.01% 2039
2020
Q1 		$124K Hold
2,700
– – ﹤0.01% 1577
2019
Q4 		$162K Hold
2,700
– – ﹤0.01% 1669
2019
Q3 		$153K Sell
2,700
-2,300
-46% -$129K ﹤0.01% 1647
2019
Q2 		$278K Buy
+5,000
New +$261K ﹤0.01% 1500
2019
Q1 		– Sell
-100
Closed -$4K – 2099
2018
Q4 		$4K Sell
100
-200
-67% -$10.3K ﹤0.01% 2142
2018
Q3 		$21K Sell
300
-1,200
-80% -$91K ﹤0.01% 1900
2018
Q2 		$113K Buy
1,500
+1,200
+400% +$75.5K ﹤0.01% 1813
2018
Q1 		$16K Sell
300
-3,100
-91% -$180K ﹤0.01% 2102
2017
Q4 		$182K Sell
3,400
-1,900
-36% -$106K ﹤0.01% 1756
2017
Q3 		$316K Buy
+5,300
New +$321K ﹤0.01% 1599

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Macquarie Group's EGRX Position: Q3 2024 in Review

Macquarie Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 518 shares — an estimated $2.9K sold.

Macquarie Group first reported a position in EGRX in Q3 2017 and held it in 20 quarters. The position peaked at $316K in Q3 2017. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Macquarie Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 518 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $2.9K.
  • Macquarie Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 20 quarters.
  • Macquarie Group's Eagle Pharmaceuticals, Inc. position peaked at $316K in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.